Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-007 · synthetic case CVR-FX-20
A 17-year-old is outside the adult pathway
Pediatric lipid pathway.
Purpose: Pediatric lipid pathway.
Inputs the engine received
Lipids and risk estimate
- LDL-C
- 150 mg/dL
Patient
- Age
- 17 years
What the engine reports
Use the pediatric lipid pathway; this engine is for adults.
Detected clinical pattern
Outside the Adult Pathway
Adult risk categories do not apply under age 20. No classification was produced.
Evidence and rule trace · 1 rules
Evidence
- EV-ACCAHA-CHOL-2018 · Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
Physician adjudication required. Clinical decision support for physician review. This output organizes guideline categories and risk modifiers. It does not calculate a 10-year risk, select a drug or dose, or replace a shared decision with the patient. Physician adjudication is required.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
10-year risk category (Pooled Cohort Equations)
○ Low · <5%
Lifestyle emphasis
○ Borderline · 5 to <7.5%
Enhancers inform the discussion
○ Intermediate · 7.5 to <20%
Statin discussion favored; CAC can help
○ High · ≥20%
Statin benefit is greatest
No stage is assigned for the values entered.
Lipids and risk estimate
- <100
- 100–159
- 160–189
- ≥190
- <150
- 150–499
- ≥500
- ≥1000
This engine does not calculate it.
Patient
Recent ACS, prior MI, ischemic stroke, symptomatic PAD.
Age ≥65, HeFH, prior revascularization, diabetes, hypertension, CKD, smoking, HF.
Risk enhancers and extra tests
Treatment and familial risk
More cardio cases
CVR-FX-01
Prior myocardial infarction, LDL-C 88 on a statin
Secondary prevention, not very high risk.
CVR-FX-02
Very high risk with LDL-C 62 on maximal therapy
Two events: the threshold is 55.
CVR-FX-03
LDL-C 205 and tendon xanthomas
Severe hypercholesterolemia.
CVR-FX-04
Diabetes at 58 with LDL-C 110
A guideline statin group.
CVR-FX-05
Intermediate risk 12% with enhancers
Family history and an hs-CRP of 3.4.
CVR-FX-06
Borderline risk 6.0%, no enhancers
Nothing to push the decision either way.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.